| TBV-08 |
DNA | 47 |
Thrombin |
8.1 pM |
| 2012 |
Nucleic Acids Research |
AptaNexus |
| 16T |
DNA | 61 |
Thrombin |
120 pM |
| 2012 |
Nucleic Acids Research |
AptaNexus |
| TBA1 |
DNA | 64 |
Thrombin |
≈ 200 pM |
| 2009 |
doi:10.3410/f.2348958.1976056 |
AptaNexus |
| HD22 |
DNA | 26 |
Thrombin |
300 pM |
| 2006 |
Journal of Biological Chemistry |
AptaNexus |
| Thr-08 |
DNA | 60 |
Thrombin |
330 pM |
| 2011 |
PLoS ONE |
AptaNexus |
| 30-8 |
DNA | 75 |
Thrombin, Human |
400 pM source Kd |
| |
doi:10.1006/jmbi.1997.1275 |
UTexas |
| Thrombin (29mer) |
DNA | 29 |
Thrombin |
500 pM |
| |
Tasset, D. (1997). Oligonucleotide inhi… |
APTABASE |
| 60-18[38] |
DNA | 38 |
Thrombin, Human |
500 pM source Kd |
| |
doi:10.1006/jmbi.1997.1275 |
UTexas |
| 60-18[29] |
DNA | 29 |
Thrombin, Human |
500 pM source Kd |
| |
doi:10.1006/jmbi.1997.1275 |
UTexas |
| Thrombin aptamer |
RNA | 25 |
Human thrombin |
540 pM |
| |
PMID 11735341 |
Ribocentre |
| 60-18[27] |
DNA | 27 |
Thrombin, Human |
700 pM source Kd |
| |
doi:10.1006/jmbi.1997.1275 |
UTexas |
| 30-38[29] |
DNA | 29 |
Thrombin, Human |
900 pM source Kd |
| |
doi:10.1006/jmbi.1997.1275 |
UTexas |
| 60-18 |
DNA | 105 |
Thrombin, Human |
920 pM source Kd |
| |
doi:10.1006/jmbi.1997.1275 |
UTexas |
| 30-14 |
DNA | 75 |
Thrombin, Human |
960 pM source Kd |
| |
doi:10.1006/jmbi.1997.1275 |
UTexas |
| Tbn#3 |
RNA | 39 |
Thrombin |
1.4 nM |
| 2018 |
Biology Methods and Protocols |
AptaNexus |
| T.7(40) |
DNA | 42 |
Thrombin |
1.5 nM |
| 2023 |
Nature Biotechnology |
AptaNexus |
| T.7(90) |
DNA | 73 |
Thrombin |
1.5 nM |
| 2023 |
Nature Biotechnology |
AptaNexus |
| T.7(46) |
DNA | 34 |
Thrombin |
1.5 nM |
| 2023 |
Nature Biotechnology |
AptaNexus |
| TBL1 |
DNA | 40 |
Thrombin |
1.6 nM |
| 2020 |
ACS Synthetic Biology |
AptaNexus |
| Tbn#6 |
RNA | 39 |
Thrombin |
1.7 nM |
| 2018 |
Biology Methods and Protocols |
AptaNexus |
| Thrombin aptamer |
RNA | 80 |
Human thrombin |
2.8 nM |
| |
PMID 11735341 |
Ribocentre |
| Toggle-25 |
RNA | 80 |
Thrombin, Human and porcine |
2.8 nM source Kd |
| |
doi:10.1006/mthe.2001.0495 |
UTexas |
| M04 |
DNA | 69 |
Thrombin |
4.5 nM |
| 2019 |
Molecular Therapy: Nucleic Acids |
AptaNexus |
| CII-1-37 |
RNA | 73 |
Alpha-thrombin (α-thrombin), Human |
4.7 nM source Kd |
| |
doi:10.1093/nar/gki578 |
UTexas |
| M03 |
DNA | 70 |
Thrombin |
5.4 nM |
| 2019 |
Molecular Therapy: Nucleic Acids |
AptaNexus |
| M08 |
DNA | 53 |
Thrombin |
6.07 nM range |
| 2019 |
Molecular Therapy: Nucleic Acids |
AptaNexus |
| cTT-2 |
DNA | 48 |
Thrombin |
7 nM |
| 2005 |
ChemBioChem |
AptaNexus |
| M08s-1 |
DNA | 44 |
Thrombin |
7 nM |
| 2019 |
Molecular Therapy: Nucleic Acids |
AptaNexus |
| Toehold-M08s-1 |
DNA | 59 |
Thrombin |
7 nM |
| 2019 |
Molecular Therapy: Nucleic Acids |
AptaNexus |
| M06 |
DNA | 70 |
Thrombin |
8.2 nM |
| 2019 |
Molecular Therapy: Nucleic Acids |
AptaNexus |
| 16.24 |
RNA | 24 |
α-Thrombin, Human |
9.3 nM source Kd |
| |
doi:10.1093/nar/22.13.2619 |
UTexas |
| RNAR9D-14T |
RNA, modified | 58 |
Thrombin |
10 nM |
| 2012 |
Journal of Thrombosis and Haemostasis |
AptaNexus |
| A#1 |
DNA, modified | 29 |
Thrombin |
10 nM |
| 2014 |
Molecular Biosystems |
AptaNexus |
| Tb-2.2 |
DNA | 13 |
Thrombin |
16.3 nM |
| 2025 |
Analytical Chemistry |
AptaNexus |
| TBL2 |
DNA | 40 |
Thrombin |
16.7 nM |
| 2020 |
ACS Synthetic Biology |
AptaNexus |
| Tb-2 |
DNA | 35 |
Thrombin |
16.9 nM |
| 2025 |
Analytical Chemistry |
AptaNexus |
| Tb-2.1 |
DNA | 20 |
Thrombin |
17.4 nM |
| 2025 |
Analytical Chemistry |
AptaNexus |
| 2′,4′-BNA/LNA (A#40) |
DNA, modified | 70 |
Thrombin, Human |
18 nM source Kd |
| |
doi:10.1016/j.bmcl.2012.12.093 |
UTexas |
| cUB-1 |
DNA | 37 |
Thrombin |
≈ 20 nM |
| 2005 |
ChemBioChem |
AptaNexus |
| 2′,4′-BNA/LNA (A#23) |
DNA, modified | 70 |
Thrombin, Human |
20 nM source Kd |
| |
doi:10.1016/j.bmcl.2012.12.093 |
UTexas |
| L-13 |
DNA | 46 |
Thrombin |
22 nM |
| 2022 |
NATURE BIOTECHNOLOGY |
AptaNexus |
| 2′,4′-BNA/LNA (A#17) |
DNA, modified | 70 |
Thrombin, Human |
23 nM source Kd |
| |
doi:10.1016/j.bmcl.2012.12.093 |
UTexas |
| ThEV.G4.04422 |
DNA | 29 |
Thrombin |
24 nM |
| 2009 |
Analytical Biochemistry |
AptaNexus |
| B4 |
RNA | 31 |
Thrombin |
26 nM |
| 2006 |
Oligonucleotides |
AptaNexus |
| A#4 |
DNA | 25 |
Thrombin |
27 nM |
| 2014 |
Molecular Biosystems |
AptaNexus |
| 2′,4′-BNA/LNA (A#18) |
DNA, modified | 70 |
Thrombin, Human |
27 nM source Kd |
| |
doi:10.1016/j.bmcl.2012.12.093 |
UTexas |
| cTSA-2 |
DNA | 107 |
Thrombin, L-selectin |
29 nM |
| 2005 |
ChemBioChem |
AptaNexus |
| 30-16[29] |
DNA | 29 |
Thrombin, Human |
30 nM source Kd |
| |
doi:10.1006/jmbi.1997.1275 |
UTexas |
| 16 |
RNA | 78 |
α-Thrombin, Human |
37 nM source Kd |
| |
doi:10.1093/nar/22.13.2619 |
UTexas |
| L-9-1t |
DNA | 42 |
Thrombin |
39 nM |
| 2022 |
NATURE BIOTECHNOLOGY |
AptaNexus |
| 30-38[27] |
DNA | 27 |
Thrombin, Human |
42 nM source Kd |
| |
doi:10.1006/jmbi.1997.1275 |
UTexas |
| Tb-5 |
DNA | 26 |
Thrombin |
43.4 nM |
| 2025 |
Analytical Chemistry |
AptaNexus |
| A#25 |
DNA, modified | 30 |
Thrombin |
45 nM |
| 2014 |
Molecular Biosystems |
AptaNexus |
| C03 |
DNA | 70 |
Thrombin |
57 nM |
| 2019 |
Molecular Therapy: Nucleic Acids |
AptaNexus |
| M10 |
DNA | 72 |
Thrombin |
59.4 nM |
| 2019 |
Molecular Therapy: Nucleic Acids |
AptaNexus |
| C06 |
DNA | 70 |
Thrombin |
63 nM |
| 2019 |
Molecular Therapy: Nucleic Acids |
AptaNexus |
| C04 |
DNA | 70 |
Thrombin |
66 nM |
| 2019 |
Molecular Therapy: Nucleic Acids |
AptaNexus |
| Unnamed |
DNA | 50 |
Thrombin |
≈ 75 nM |
| 2007 |
Analytical Biochemistry |
AptaNexus |
| SRA_3 |
DNA | 60 |
Thrombin |
76 nM |
| 2010 |
PNAS |
AptaNexus |
| SRA_1 |
DNA | 61 |
Thrombin |
77 nM |
| 2010 |
PNAS |
AptaNexus |
| Tb-19 |
DNA | 58 |
Thrombin |
81.4 nM |
| 2025 |
Analytical Chemistry |
AptaNexus |
| SRA_2 |
DNA | 61 |
Thrombin |
83 nM |
| 2010 |
PNAS |
AptaNexus |
| Thrombin (15mer) |
DNA | 15 |
Thrombin |
84 nM |
| |
(A) Bock, Louis, et al. "Selection of s… |
APTABASE |
| A#11 |
DNA, modified | 30 |
Thrombin |
84 nM |
| 2014 |
Molecular Biosystems |
AptaNexus |
| Seq-1 |
DNA | 62 |
Thrombin |
98.2 nM |
| 2019 |
Analytica Chimica Acta |
AptaNexus |
| C08 |
DNA | 70 |
Thrombin |
102 nM |
| 2019 |
Molecular Therapy: Nucleic Acids |
AptaNexus |
| Apt-1 |
DNA | 21 |
Thrombin |
111 nM |
| 2021 |
Chemistry—A European Journal |
AptaNexus |
| 15 mer (colloquially known as Bock DNA Aptamer) |
DNA | 15 |
Thrombin (Sigma), Human |
112 nM source Kd |
| |
doi:10.1038/355564a0 |
UTexas |
| 6 mer (colloquially known as Bock DNA Aptamer) |
DNA | 6 |
Thrombin (Sigma), Human |
112 nM source Kd |
| |
doi:10.1038/355564a0 |
UTexas |
| 27 |
RNA | 75 |
α-Thrombin, Human |
114 nM source Kd |
| |
doi:10.1093/nar/22.13.2619 |
UTexas |
| 30-16[27] |
DNA | 27 |
Thrombin, Human |
126 nM source Kd |
| |
doi:10.1006/jmbi.1997.1275 |
UTexas |
| C10 |
DNA | 70 |
Thrombin |
140 nM |
| 2019 |
Molecular Therapy: Nucleic Acids |
AptaNexus |
| 27.33 |
RNA | 33 |
α-Thrombin, Human |
155 nM source Kd |
| |
doi:10.1093/nar/22.13.2619 |
UTexas |
| Bovine thrombin aptamer |
RNA | 68 |
Bovine thrombin |
164 nM |
| |
PMID 12557236 |
Ribocentre |
| T705 |
RNA | 68 |
Thrombin, Bovine |
164 nM source Kd |
| |
doi:10.1002/jmr.604 |
UTexas |
| Thb1_Rank3 |
DNA | 15 |
Thrombin |
170 nM |
| 2011 |
PLoS ONE |
AptaNexus |
| C05 |
DNA | 70 |
Thrombin |
173 nM |
| 2019 |
Molecular Therapy: Nucleic Acids |
AptaNexus |
| M01 |
DNA | 70 |
Thrombin |
179 nM |
| 2019 |
Molecular Therapy: Nucleic Acids |
AptaNexus |
| Seq-2 |
DNA | 18 |
Thrombin |
200 nM |
| 2019 |
Analytica Chimica Acta |
AptaNexus |
| C2 |
RNA | 29 |
Thrombin |
200 nM |
| 2006 |
Oligonucleotides |
AptaNexus |
| M07 |
DNA | 71 |
Thrombin |
231 nM |
| 2019 |
Molecular Therapy: Nucleic Acids |
AptaNexus |
| Bovine thrombin aptamer |
RNA | 68 |
Bovine thrombin |
240 nM |
| |
PMID 12557236 |
Ribocentre |
| T710 |
RNA | 68 |
Thrombin, Bovine |
240 nM source Kd |
| |
doi:10.1002/jmr.604 |
UTexas |
| C07 |
DNA | 70 |
Thrombin |
270 nM |
| 2019 |
Molecular Therapy: Nucleic Acids |
AptaNexus |
| Unnamed |
DNA | 76 |
Thrombin |
307 nM |
| 2017 |
Journal of the American Chemical Society |
AptaNexus |
| RNAmut |
RNA, modified | 58 |
Thrombin |
1 µM |
| 2012 |
Journal of Thrombosis and Haemostasis |
AptaNexus |
| Thb1_Rank25 |
DNA | 15 |
Thrombin |
2.2 µM |
| 2011 |
PLoS ONE |
AptaNexus |
| TBL3 |
DNA | 41 |
Thrombin |
2.3 µM |
| 2020 |
ACS Synthetic Biology |
AptaNexus |
| C01 |
DNA | 70 |
Thrombin |
3.58 µM |
| 2019 |
Molecular Therapy: Nucleic Acids |
AptaNexus |
| Aptamer 1 |
DNA | 15 |
Alpha thrombin (α-thrombin), Human |
3.87 µM range |
| |
doi:10.1006/bbrc.1994.1539 |
UTexas |
| Aptamer 2 |
DNA | 15 |
Alpha thrombin (α-thrombin), Human |
3.87 µM range |
| |
doi:10.1006/bbrc.1994.1539 |
UTexas |
| Aptamer 3 |
DNA | 15 |
Alpha thrombin (α-thrombin), Human |
3.87 µM range |
| |
doi:10.1006/bbrc.1994.1539 |
UTexas |
| 4A018 |
DNA | 50 |
Thrombin |
4 µM |
| 2015 |
Journal of Nucleic Acids |
AptaNexus |
| C02 |
DNA | 70 |
Thrombin |
5.28 µM |
| 2019 |
Molecular Therapy: Nucleic Acids |
AptaNexus |
| Thrombin (31mer) (D2-5) |
DNA | 31 |
Thrombin |
– |
| |
K Ikebukuro et al. Analysis of the evol… |
APTABASE |
| TBA2 |
DNA | 64 |
Thrombin |
– |
| 2009 |
doi:10.3410/f.2348958.1976056 |
AptaNexus |
| The other1 |
DNA | 33 |
Thrombin |
– |
| 2009 |
doi:10.3410/f.2348958.1976056 |
AptaNexus |
| The other2 |
DNA | 36 |
Thrombin |
– |
| 2009 |
doi:10.3410/f.2348958.1976056 |
AptaNexus |
| The other3 |
DNA | 33 |
Thrombin |
– |
| 2009 |
doi:10.3410/f.2348958.1976056 |
AptaNexus |
| The other4 |
DNA | 33 |
Thrombin |
– |
| 2009 |
doi:10.3410/f.2348958.1976056 |
AptaNexus |
| The other5 |
DNA | 33 |
Thrombin |
– |
| 2009 |
doi:10.3410/f.2348958.1976056 |
AptaNexus |
| The other6 |
DNA | 34 |
Thrombin |
– |
| 2009 |
doi:10.3410/f.2348958.1976056 |
AptaNexus |
| Apta-1 |
RNA, modified | 90 |
Thrombin |
– |
| 2025 |
British Journal of Pharmacology |
AptaNexus |
| 15mer_Bock |
DNA | 13 |
Thrombin |
– |
| 2011 |
BioTechniques |
AptaNexus |
| 15mer_GGGTGGTTGGTTGG |
DNA | 14 |
Thrombin |
– |
| 2011 |
BioTechniques |
AptaNexus |
| Positive_control |
DNA | 38 |
Thrombin |
– |
| 2011 |
BioTechniques |
AptaNexus |
| 15mer_GGTTGGTGGTGG |
DNA | 12 |
Thrombin |
– |
| 2011 |
BioTechniques |
AptaNexus |
| 15mer_TTGGTTTGGTTGTTT |
DNA | 15 |
Thrombin |
– |
| 2011 |
BioTechniques |
AptaNexus |
| 15mer_GGTTGGGTTGGTTGG |
DNA | 15 |
Thrombin |
– |
| 2011 |
BioTechniques |
AptaNexus |
| 16mer_TGGTGTTGGTAGA |
DNA | 14 |
Thrombin |
– |
| 2011 |
BioTechniques |
AptaNexus |
| 16mer_GGTTGGTTGTTGT |
DNA | 13 |
Thrombin |
– |
| 2011 |
BioTechniques |
AptaNexus |
| 16mer_GGTTTGTTTGGtGGT |
DNA | 15 |
Thrombin |
– |
| 2011 |
BioTechniques |
AptaNexus |
| 16mer_GGTATGGTTTGGTTGG |
DNA | 16 |
Thrombin |
– |
| 2011 |
BioTechniques |
AptaNexus |
| 16mer_GGTGGTTGGTTGGTTG |
DNA | 16 |
Thrombin |
– |
| 2011 |
BioTechniques |
AptaNexus |
| Clone 7 |
RNA | 25 |
Thrombin |
– |
| 2017 |
Chem. Commun. |
AptaNexus |
| 6-7 |
DNA | 15 |
Thrombin |
– |
| 2005 |
Nucleic Acids Research |
AptaNexus |
| 7-1 |
DNA | 15 |
Thrombin |
– |
| 2005 |
Nucleic Acids Research |
AptaNexus |
| 6-1 |
DNA | 15 |
Thrombin |
– |
| 2005 |
Nucleic Acids Research |
AptaNexus |
| 6-6 |
DNA | 15 |
Thrombin |
– |
| 2005 |
Nucleic Acids Research |
AptaNexus |
| 4-10 |
DNA | 15 |
Thrombin |
– |
| 2005 |
Nucleic Acids Research |
AptaNexus |
| L4-2 |
DNA | 31 |
Thrombin |
– |
| 2005 |
Nucleic Acids Research |
AptaNexus |
| ThA |
DNA | 20 |
Thrombin |
– |
| 2022 |
PLoS Computational Biology |
AptaNexus |
| ThD |
DNA | 20 |
Thrombin |
– |
| 2022 |
PLoS Computational Biology |
AptaNexus |
| r1 |
DNA | 20 |
Thrombin |
– |
| 2022 |
PLoS Computational Biology |
AptaNexus |
| r2 |
DNA | 20 |
Thrombin |
– |
| 2022 |
PLoS Computational Biology |
AptaNexus |
| r3 |
DNA | 20 |
Thrombin |
– |
| 2022 |
PLoS Computational Biology |
AptaNexus |
| r4 |
DNA | 20 |
Thrombin |
– |
| 2022 |
PLoS Computational Biology |
AptaNexus |
| r5 |
DNA | 20 |
Thrombin |
– |
| 2022 |
PLoS Computational Biology |
AptaNexus |
| r6 |
DNA | 20 |
Thrombin |
– |
| 2022 |
PLoS Computational Biology |
AptaNexus |
| r7 |
DNA | 20 |
Thrombin |
– |
| 2022 |
PLoS Computational Biology |
AptaNexus |
| r8 |
DNA | 20 |
Thrombin |
– |
| 2022 |
PLoS Computational Biology |
AptaNexus |
| r9 |
DNA | 20 |
Thrombin |
– |
| 2022 |
PLoS Computational Biology |
AptaNexus |
| r10 |
DNA | 20 |
Thrombin |
– |
| 2022 |
PLoS Computational Biology |
AptaNexus |
| r11 |
DNA | 20 |
Thrombin |
– |
| 2022 |
PLoS Computational Biology |
AptaNexus |
| r12 |
DNA | 20 |
Thrombin |
– |
| 2022 |
PLoS Computational Biology |
AptaNexus |
| r13 |
DNA | 20 |
Thrombin |
– |
| 2022 |
PLoS Computational Biology |
AptaNexus |
| r14 |
DNA | 20 |
Thrombin |
– |
| 2022 |
PLoS Computational Biology |
AptaNexus |
| r15 |
DNA | 20 |
Thrombin |
– |
| 2022 |
PLoS Computational Biology |
AptaNexus |
| r16 |
DNA | 20 |
Thrombin |
– |
| 2022 |
PLoS Computational Biology |
AptaNexus |
| r17 |
DNA | 20 |
Thrombin |
– |
| 2022 |
PLoS Computational Biology |
AptaNexus |
| r18 |
DNA | 20 |
Thrombin |
– |
| 2022 |
PLoS Computational Biology |
AptaNexus |
| r19 |
DNA | 20 |
Thrombin |
– |
| 2022 |
PLoS Computational Biology |
AptaNexus |
| r20 |
DNA | 20 |
Thrombin |
– |
| 2022 |
PLoS Computational Biology |
AptaNexus |
| r21 |
DNA | 20 |
Thrombin |
– |
| 2022 |
PLoS Computational Biology |
AptaNexus |
| r22 |
DNA | 20 |
Thrombin |
– |
| 2022 |
PLoS Computational Biology |
AptaNexus |
| r23 |
DNA | 20 |
Thrombin |
– |
| 2022 |
PLoS Computational Biology |
AptaNexus |
| r24 |
DNA | 20 |
Thrombin |
– |
| 2022 |
PLoS Computational Biology |
AptaNexus |
| r25 |
DNA | 20 |
Thrombin |
– |
| 2022 |
PLoS Computational Biology |
AptaNexus |
| r26 |
DNA | 20 |
Thrombin |
– |
| 2022 |
PLoS Computational Biology |
AptaNexus |
| r27 |
DNA | 20 |
Thrombin |
– |
| 2022 |
PLoS Computational Biology |
AptaNexus |
| ThB |
DNA | 20 |
Thrombin |
– |
| 2022 |
PLoS Computational Biology |
AptaNexus |
| ThC |
DNA | 20 |
Thrombin |
– |
| 2022 |
PLoS Computational Biology |
AptaNexus |
| p1 |
DNA | 20 |
Thrombin |
– |
| 2022 |
PLoS Computational Biology |
AptaNexus |
| p2 |
DNA | 20 |
Thrombin |
– |
| 2022 |
PLoS Computational Biology |
AptaNexus |
| p3 |
DNA | 20 |
Thrombin |
– |
| 2022 |
PLoS Computational Biology |
AptaNexus |
| p4 |
DNA | 20 |
Thrombin |
– |
| 2022 |
PLoS Computational Biology |
AptaNexus |
| p5 |
DNA | 20 |
Thrombin |
– |
| 2022 |
PLoS Computational Biology |
AptaNexus |
| p6 |
DNA | 20 |
Thrombin |
– |
| 2022 |
PLoS Computational Biology |
AptaNexus |
| AES SARS 3 |
DNA | 61 |
Thrombin |
– |
| 2006 |
Biochemical and Biophysical Research Communications |
AptaNexus |
| AES 1 |
DNA | 56 |
Thrombin |
– |
| 2006 |
Biochemical and Biophysical Research Communications |
AptaNexus |
| AES 2 |
DNA | 58 |
Thrombin |
– |
| 2006 |
Biochemical and Biophysical Research Communications |
AptaNexus |
| AES SARS 1 |
DNA | 58 |
Thrombin |
– |
| 2006 |
Biochemical and Biophysical Research Communications |
AptaNexus |
| CCN control |
DNA | 27 |
Thrombin |
– |
| 2006 |
ChemBioChem |
AptaNexus |
| Rank51 |
DNA | 15 |
Thrombin |
– |
| 2011 |
PLoS ONE |
AptaNexus |
| Thr-02 |
DNA | 60 |
Thrombin |
– |
| 2011 |
PLoS ONE |
AptaNexus |
| Rank54 |
DNA | 15 |
Thrombin |
– |
| 2011 |
PLoS ONE |
AptaNexus |
| Rank56 |
DNA | 15 |
Thrombin |
– |
| 2011 |
PLoS ONE |
AptaNexus |
| Rank121 |
DNA | 15 |
Thrombin |
– |
| 2011 |
PLoS ONE |
AptaNexus |
| M05 |
DNA | 70 |
Thrombin |
– |
| 2019 |
Molecular Therapy: Nucleic Acids |
AptaNexus |
| M02 |
DNA | 70 |
Thrombin |
– |
| 2019 |
Molecular Therapy: Nucleic Acids |
AptaNexus |
| M09 |
DNA | 70 |
Thrombin |
– |
| 2019 |
Molecular Therapy: Nucleic Acids |
AptaNexus |
| C09 |
DNA | 70 |
Thrombin |
– |
| 2019 |
Molecular Therapy: Nucleic Acids |
AptaNexus |
| 30-16 |
DNA | 75 |
Thrombin, Human |
– |
| |
doi:10.1006/jmbi.1997.1275 |
UTexas |
| 30-38 |
DNA | 75 |
Thrombin, Human |
– |
| |
doi:10.1006/jmbi.1997.1275 |
UTexas |
| CI-2-23 |
RNA | 66 |
Alpha-thrombin (α-thrombin), Human |
– |
| |
doi:10.1093/nar/gki578 |
UTexas |